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strated superior efﬁcacy to placebo in the three co-primary end-
points of WOMAC™ pain and function, and subject’s overall rating
of disease status (p≤0.0004). In addition, naproxcinod 750 mg bid
was non-inferior to naproxen 500 mg bid at Week 13.
The percentage of subjects with at least one treatment emergent
AE was 47.0%, 46.4%, for naproxcinod 375 and 750 mg bid,
respectively, 47.7% for naproxen and 44.8% for placebo.
Conclusions: This study demonstrated the clinical efﬁcacy of
naproxcinod 375 mg bid and 750 mg bid over placebo after 13
weeks of treatment, conﬁrming the results of previous clinical
trials. Both doses of naproxcinod were safe and well tolerated.
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Purpose: To evaluate the long-term safety of tanezumab, a hu-
manized monoclonal antibody speciﬁc for nerve growth factor, in
patients with knee pain due to osteoarthritis (OA).
Methods: Male and female patients aged 40-78 years who had
received 2 infusions of tanezumab in a Phase II, 16 week, placebo-
controlled multiple-dose study (Study 1008) and been followed for
≥8 weeks after the last infusion, were eligible to enrol in this
open-label extension study to evaluate the long-term safety and
efﬁcacy of tanezumab for the treatment of osteoarthritic knee pain.
Patients received tanezumab 50 μg/kg (IV) on Days 1 and 56, and
at subsequent 8 week intervals at the discretion of the investigator.
Safety assessments including adverse event (AE) documentation,
physical and neurological examinations, Hopkins Verbal Learning
Test-Revised (HVLT-R), vital signs, blood tests, urinalysis and 12-
lead ECG were performed at each visit until termination, 12 weeks
after the last dose of tanezumab. Patients who received ≥1 study
drug infusion (in this study) were included in the safety analysis.
Results: Of 281 patients assigned to open-label treatment, similar
numbers came from each treatment arm (placebo or tanezumab
10, 25, 50, 100 or 200 μg/kg) of Study 1008. Patients were 39%
male, 89% white, with a mean (±SD) age of 59 (±8.1) years. They
received between 1 and 8 infusions of 50 μg/kg tanezumab over a
mean (±SD) period of 224 (±117) days (range 1-484 days). Over-
all, 168 (59.8%) patients reported 446 all-cause AEs, of which the
most frequently reported (>5% of patients) were arthralgia (6.8%),
back pain (6.0%), and headache (5.7%). All-cause AEs suggestive
of abnormal peripheral sensation (hyperaesthesia, hypoaesthesia,
peripheral neuropathy, paraesthesia, sensory disturbance) were
reported by 18 (6.4%) patients, in 17 of whom the AE was mild in
intensity and in 1 of whom it was severe (peripheral neuropathy).
Hypoesthesia (3.2%) was the most frequent AE suggestive of
abnormal peripheral sensation. Allodynia and dysaesthesia were
not reported by any patient. In total, 21 (7.5%) patients reported
28 treatment-related AEs, of which the most frequent (≥2 pa-
tients) were hypoaesthesia (1.1%), paraesthesia (1.1%), dizziness
(0.7%), and peripheral oedema (0.7%). Of the 19 (6.8%) patients
who discontinued treatment due to an AE, 4 discontinued due to
treatment-related AEs (hypoaesthesia; adjustment disorders with
depressed mood; diarrhoea; and prolonged ECG QT). No vital
sign, physical, or neurological examination was reported as an
AE and there was no notable decrease in mean change from
baseline in total and delayed recall HVLT-R scores. A serious AE
(SAE), irrespective of causality, was reported by 8 (2.8%) patients,
but none was considered to be treatment-related. There were no
deaths. In addition, pain relief (improvement in overall knee pain
and walking pain) was maintained during open-label treatment of
up to 1 year in duration.
Conclusions: Repeat doses of tanezumab 50 μg/kg, given to
patients with moderate to severe osteoarthritic knee pain were
safe and well tolerated over the long term. AEs suggestive of
abnormal peripheral sensation were transient and almost all were
mild in intensity. Tanezumab also provided sustained and effective
analgesia.
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Purpose: Knee OA in its most severe form is a wasting disease
that causes pain, stiffness and disability. As there are no known
cure for OA the treatment is aimed at symptoms by use of pain
killers, NSAIDs, physiotherapy and braces. Osteotomies where the
load on the symptomatic compartment of the knee is reduced by
changing alignment in the knee is a alternative. In severe OA joint
replacement is often the only choice.
Unloader (valgus) braces are designed to decrease the load on the
symptomatic compartment of the OA knee by changing alignment.
This should reduce pain and improve function. The purpose of this
study is to document outcomes following 6 months of use of an
Unloader brace in a cohort of patients with knee OA.
Methods: Patients who were diagnosed by orthopedic surgeons,
general practitioners and rheumatologists with knee OA and had
prescription for Unloader brace because of unicompartmental
symptomatic knee OA were enrolled in the study. The knee
OA was graded according to Kellgrene & Lawrence classiﬁcation
from weight bearing radiographs of both knees (P/A weight bear-
ing/semi ﬂexed and lateral supine). Patients with mild, moderate
or severe unicompartmental knee OA and even patients who were
waiting for knee arthroplasty were included. The WOMAC index
(version 3.1) was the main instrument used to assess the severity
of the symptoms. This consists of 24 items in 3 subscales: pain
(5), stiffness (2), and physical function (17). Component items are
measured on a 5-point Likert scale with higher scores indicating
greater symptom severity.
It was an IRB approved prospective cohort study and the pa-
tients signed informed consent before answering questionnaires.
First before receiving the Unloder then after 3 weeks, 3 months
and 6 months. The main outcomes in the analysis were the
three WOMAC subscale scores (pain, stiffness, function) and the
combined Total WOMAC score. Exposure variables considered in
analyses were: Age, Gender, BMI and K& L grade (0, 1, 2, 3, 4).
Results: 82 patients participated in the study. 33 women mean
age 59.7 years (40-81), 49 men average age 60.9 years (38-85).
Mean BMI (SD) in men was 30.3 (±5.0) and in women 31.0 (±6.1).
Five patients discontinued using the brace because of pain during
the study. Three patients only answered the ﬁrst questionnaire.
Eight patients were on waiting lists for knee arthroplasty when the
brace where prescribed and 5 of them where operated during the
study time. 75 of the patients had radiographic medial knee OA
and according to the K&L classiﬁcation, 13 grade I, 25 grade II, 32
grade III and 11 grade IV. Seven patients had radiographic lateral
knee OA, 4 grade III and 3 grade II. Seventy-ﬁve were prescribed
a medial Unloader brace and seven lateral.
Total WOMAC score at baseline was 50 and decreased to 34 after
three week. The improvement continued for six months. This is a
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moderate to high responsiveness according to OARSI criteria.After
3 weeks all subscales showed signiﬁcant improvements compared
to baseline (pain (p<0.001), stiffness (p<0.001) and function
(p<0.001)). No correlation where between the severity of OA
(K&L) and improvement in WOMAC score. The only variable (age,
gender, side, BMI, K&L, medial/lateral) which had a signiﬁcant
effect on WOMAC score was gender, women had higher score.
Quality of live during the study time improved according to EQ-5D.
Conclusions: Conclusions: An Unloading knee brace did de-
crease pain and improve function as shown by signiﬁcant im-
provement in WOMAC score for pain, stiffness, function and total
score. An Unloader brace is a treatment alternative even in mod-
erate and severe unicompartmental knee OA.
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Purpose: The aim of the study was to evaluate the clinical efﬁ-
cacy and safety of CG100649 administered in different dosages.
CG100649 is a ﬁrst-in-class NSAID candidate with a new mode
of “tissue-speciﬁc” activity designed to deliver sustained levels of
drug to inﬂamed tissues while maintaining low systemic exposure
by binding to carbonic anhydrase (CA) in red blood cells. Previous
Phase I clinical studies have shown that CG100649 has a unique
pharmacokinetic (PK) proﬁle with 85-100x higher concentrations
in whole blood (drug transport via erythrocytes that have high con-
centrations of CA) than in plasma (no CA). Synovial ﬂuid has been
shown to have little or no CA. Thus, CG100649 was hypothesized
to achieve maximum efﬁcacy in inﬂamed joints while minimizing
its impact on the cardio-renal system or GI tract.
Methods: Clinical trial CG100649-2-01 was a randomized, double-
blind study in male subjects, 18-75 years old, with a 3 month or
longer history of primary osteoarthritis (OA) of the hip or knee.
The study was conducted in 248 subjects at 25 investigative sites
in Germany, Hungary, and Ukraine. The trial was designed to
evaluate the safety and efﬁcacy of three parallel dose regimens of
CG100649 vs. placebo in the treatment of OA. After a 5-14 day
washout period from other pain relief medications, all doses were
administered orally, once a day in the morning. Initial loading doses
(Day 0) and maintenance doses (Days 1-20) were: High Dose (8
mg + 1.2 mg/day), Medium Dose (4 mg + 0.6 mg/day), and Low
Dose (2 mg + 0.3 mg/day). Subjects returned to the study center
once a week on Days 7, 14, and 21 during the treatment period
and on Days 28 and 35 during the follow-up period for safety and
efﬁcacy assessments. Efﬁcacy assessments included the Western
Ontario and McMaster Universities (WOMAC™) OA index, Brief
Pain Inventory (BPI), Subject’s Global Assessment, Physician’s
Global Assessment, withdrawals due to lack of efﬁcacy, and usage
of paracetamol (acetaminophen) as a rescue medication. Blood
pressure, ECG, and GI bleeding were monitored for potential
adverse side effects.
Results: The CG100649 high dose group showed more than a
2-fold greater magnitude of improvement than the placebo group
on the primary endpoint of change in the WOMAC score from
baseline to Day 21 (median values were 37% vs. 17%, respec-
tively; P=0.01). The study also met all key secondary endpoints,
with the high dose demonstrating clinically and statistically sig-
niﬁcant superiority over the placebo group in the WOMAC OA
score over the entire 21-day active treatment period (p=0.010)
and in the WOMAC subscales of pain, stiffness and physical
function (p=0.016, p=0.023, p=0.010, respectively) over the en-
tire 35-day treatment and follow-up evaluation periods. Weekly
pain relief scores showed statistically signiﬁcant improvements
at Days 7, 14, 21, and 28 (p<0.05 at all time periods) which
demonstrated that CG100649 had an early onset of activity and
provided sustained treatment beneﬁts over the entire treatment
period. No treatment-related changes were observed in systolic,
diastolic, or mean blood pressure in the entire subject population
or after controlling for age (younger vs. older subjects). No relevant
treatment group differences were noted for any other vital sign,
clinical laboratory parameter, ECG parameter. No subject experi-
enced gastrointestinal bleeding or other clinically relevant adverse
GI side effects.
Conclusions: These data provide the ﬁrst evidence of statistically
and clinically signiﬁcant analgesia and functional beneﬁts pro-
duced by a dual COX-2/CA inhibitor without meaningful GI and CV
side effects. All doses were well tolerated. Supported by a grant
from CrystalGenomics and partially supported from the BioStar
Program of MKE (Ministry of Knowledge Economy) of Korea.
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Purpose: Biomechanical studies of persons with medial
tibiofemoral OA demonstrate that even with appropriate valgus
knee bracing, large medial forces remain, suggesting that the
addition of other interventions to further improve limb alignment
may be of therapeutic value. The objective of this 30-week ran-
domized crossover trial was to determine whether a multi-modal
realignment therapy (consisting of valgus knee brace + motion
control shoes + neutral foot orthoses) would be successful in re-
lieving pain and improving function among persons with medial
tibiofemoral OA.
Methods: We conducted a double blind, randomized crossover
trial of a multi-modal realignment therapy for persons with me-
dial tibiofemoral OA. Trial participants met ACR criteria for OA
with knee pain, aching or stiffness on most of the past month
and radiographic evidence of a deﬁnite osteophyte. We tested
two different treatments: A) CONTROL TREATMENT consisting
of a neutral knee brace (no valgus angulation), ﬂat unsupportive
foot orthoses, and shoes with a ﬂexible midsole; and B) ACTIVE
TREATMENT consisting of a valgus knee brace, customized neu-
tral foot orthoses, and shoes designed for motion control. For
each subject, the trial lasted 30 weeks, including 12 weeks each
of active and control treatment separated by a 6-week washout pe-
riod. The primary outcome was change in knee pain and function
as assessed by the WOMAC Osteoarthritis Index (VAS version).
An unstructured correlation matrix for observations within subjects
was used in generalized estimating equation ﬁtting. The ﬁnal linear
regression model was conducted with exclusion of the differential
carryover effect.
Results: 80 participants with medial tibiofemoral OA were ran-
domized. 63% were female. Their mean age was 62 years and
mean BMI was 34 kg/m2. The main effects are depicted in Table 1.
There was no evidence of a carryover effect in the initial analyses.
